VOL. XCIV, NO. 247
★ WIDE MOAT STOCKS COMPARISON ★
NO ADVICE
Wednesday, December 31, 2025
Stock Comparison
Nasdaq, Inc. vs Novo Nordisk A/S
Compare moat strength, market structure, and segment coverage to understand how each company defends its edge.
Nasdaq, Inc.
NDAQ · NASDAQ
Weighted average of segment moat scores, combining moat strength, durability, confidence, market structure, pricing power, and market share.
Full stock profile
Dive deeper into Nasdaq, Inc.'s moat claims, evidence, and risks.
View NDAQ analysisNovo Nordisk A/S
NOVOB · Nasdaq Copenhagen
Weighted average of segment moat scores, combining moat strength, durability, confidence, market structure, pricing power, and market share.
Full stock profile
Dive deeper into Novo Nordisk A/S's moat claims, evidence, and risks.
View NOVOB analysisComparison highlights
- Moat score gap: Novo Nordisk A/S leads (85 / 100 vs 76 / 100 for Nasdaq, Inc.).
- Segment focus: Nasdaq, Inc. has 3 segments (42.4% in Capital Access Platforms); Novo Nordisk A/S has 3 segments (71.1% in Diabetes care).
- Moat breadth: Nasdaq, Inc. has 9 moat types across 5 domains; Novo Nordisk A/S has 5 across 3.
Primary market context
Nasdaq, Inc.
Capital Access Platforms
Issuer and investor solutions: listings, index licensing, market data, and investment analytics/workflow platforms
Global (with major exposure to U.S. and Nordic/Baltic markets)
Public/private companies (issuers), asset managers, institutional investors, data subscribers
Listing venue + index administrator/licensor + data/analytics provider
42.4%
Novo Nordisk A/S
Diabetes care
Diabetes pharmaceuticals (GLP-1 for type 2 diabetes, insulin, and related therapies)
Global
Payers/providers and patients (via wholesalers/pharmacies/hospitals)
Originator pharma (R&D, regulatory, manufacturing, commercialization)
71.1%
Side-by-side metrics
Moat coverage
Shared moat types
Nasdaq, Inc. strengths
Novo Nordisk A/S strengths
Segment mix
Nasdaq, Inc. segments
Full profile >Market Services
Competitive
Capital Access Platforms
Oligopoly
Financial Technology
Competitive
Novo Nordisk A/S segments
Full profile >Diabetes care
Oligopoly
Obesity care
Duopoly
Rare disease
Oligopoly
Want the full wide moat stocks list?
Browse the full ranking of wide moat stocks, updated with moat scores and segment context.
View the moat stocks listCuration & Accuracy
This directory blends AI‑assisted discovery with human curation. Entries are reviewed, edited, and organized with the goal of expanding coverage and sharpening quality over time. Your feedback helps steer improvements (because no single human can capture everything all at once).
Details change. Pricing, features, and availability may be incomplete or out of date. Treat listings as a starting point and verify on the provider’s site before making decisions. If you spot an error or a gap, send a quick note and I’ll adjust.